Sudden Cardiac Risk Assessment

Chapter
First Online:

Abstract

For the purposes of this discussion, the focus on the use of imaging as a means for risk assessment for sudden cardiac death will be limited to patients with structural heart disease with an emphasis on the detection and characterization of scar. The concept that high-­resolution imaging can detect the hallmarks of electrical instability assumes that there are specific characteristics of scar and the surrounding surviving myocardium that are indeed “arrhythmogenic.” While most of the work has focused on the detection of this at-risk tissue in patients with coronary artery disease, this chapter will also highlight the data presently available in other myopathies, including hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, and sarcoidosis. While the pathological process of these entities differs considerably, each of them shares a common endpoint of the development of scar and/or fibrosis. In addition, because the majority of the work to date has focused on using cardiac magnetic resonance imaging to risk-stratify patients for ventricular tachyarrhythmias, much of this review will highlight the use of this modality and the data presently available.

Keywords

Sudden cardiac death Imaging in assessment for sudden cardiac death Hypertrophic cardiomyopathy Arrhythmogenic right ventricular dysplasia Sarcoidosis Cardiac magnetic resonance imaging 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    American Heart Association (online September 2004) Cardiovascular disease statistics. Accessed May 23, 2005.Google Scholar
  2. 2.
    Zheng ZJ et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-2163.PubMedCrossRefGoogle Scholar
  3. 3.
    Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334-2351.PubMedGoogle Scholar
  4. 4.
    Moss AJ, Zareba W, Jackson Hall W, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.PubMedCrossRefGoogle Scholar
  5. 4a.
    Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.PubMedCrossRefGoogle Scholar
  6. 5.
    Brady G, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.CrossRefGoogle Scholar
  7. 6.
    McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med. 2005;352:222-224.PubMedCrossRefGoogle Scholar
  8. 7.
    Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. JAMA. 2005;294(8):958-960.PubMedCrossRefGoogle Scholar
  9. 8.
    Josephson ME, Horowitz LN, Farshidi A, Kastor JA. Recurrent sustained ventricular tachycardia. Mechanisms. Circulation. 1978;57:431-440.PubMedGoogle Scholar
  10. 9.
    Wit AL, Allessie MA, Bonke FI, et al. Electrophysiologic mapping to determine the mechanism of experimental ventricular tachycardia initiated by premature impulses. Experimental approach and initial results demonstrating reentrant excitation. Am J Cardiol. 1982;49(1):166-185.PubMedCrossRefGoogle Scholar
  11. 10.
    El Sherif N, Scherlag BJ, Lazzara R. Electroide cather recording during malignant ventricular arrythmia following experimental acute myocardial ischemia. Evidence for re-entry due to conduction delay and block in ischemic myocardium. Circulation. 1975;51(6):1003-1014.PubMedGoogle Scholar
  12. 11.
    de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation. 1988;77(3):589-606.PubMedCrossRefGoogle Scholar
  13. 12.
    Akhtar M, Garan H, Lehmann MH, Troup PJ. Sudden cardiac death: management of high-risk patients. Ann Intern Med. 1991;114(6):499-512.PubMedGoogle Scholar
  14. 13.
    Josephson ME, Almendral JM, Buxton AE, Marchlinski FE. Mechanisms of ventricular tachycardia. Circulation. 1987;75(4 pt 2):III41-III47.PubMedGoogle Scholar
  15. 14.
    Garan H, Fallon JT, Rosenthal S, Ruskin JN. Endocardial, intramural, and epicardial activation patterns during sustained monomorphic ventricular tachycardia in late canine myocardial infarction. Circ Res. 1987;60(6):879-896.PubMedGoogle Scholar
  16. 15.
    Peters NS, Coromilas J, Severs NJ, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation. 1997;95(4):988-996.PubMedGoogle Scholar
  17. 16.
    Yao JA, Hussain W, Patel P, Peters NS, Boyden PA, Wit AL. Remodeling of gap junctional channel function in epicardial border zone of healing canine infarcts. Circ Res. 2003;92(4):437-443.PubMedCrossRefGoogle Scholar
  18. 17.
    Stevenson WG, Friedman PL, Sager PT, et al. Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. J Am Coll Cardiol. 1997;29(6):1180-1189.PubMedCrossRefGoogle Scholar
  19. 18.
    Fenoglio JJ Jr, Pham TD, Harken AH, Horowitz LN, Josephson ME, Al W. Recurrent sustained ventricular tachycardia: structure and ultrastructure of subendocardial regions in which tachycardia originates. Circulation. 1983;68(3):518-533.PubMedCrossRefGoogle Scholar
  20. 19.
    Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation. 2001;104(6):664-669.PubMedCrossRefGoogle Scholar
  21. 20.
    de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the infracted, Langendoff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol. 1990;15(7):1594-1607.PubMedCrossRefGoogle Scholar
  22. 21.
    de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the infracted human heart. ‘Zigzag’ course of activation. Circulation. 1993;88(3):915-926.PubMedGoogle Scholar
  23. 22.
    Dillon SM, Allessie AM, Ursell PC, Wit AL. Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. Circ Res. 1988;63(1):182-206.PubMedGoogle Scholar
  24. 23.
    Wit AL, Dillon SM, Coromilas J, Saltman AE, Waldecker B. Anisotropic reentry in the epicardial border zone of myocardial infarcts. Ann N Y Acad Sci. 1990;591:86-108.PubMedCrossRefGoogle Scholar
  25. 24.
    Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117:211-221.PubMedCrossRefGoogle Scholar
  26. 25.
    Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta analysis. J Am Coll Cardiol. 2002;39:1151-1158.PubMedCrossRefGoogle Scholar
  27. 26.
    Toda K, Mackenzie K, Mehra MR, et al. Revascularization in severe ventricular dysfunction (15%  <  OR  =  LVEF  <  OR  =  30%): a comparison of bypass grafting and percutaneous intervention. Ann Thorac Surg. 2002;74(6):2082-2087.PubMedCrossRefGoogle Scholar
  28. 27.
    Bell MR, Gersh BJ, Schaff HV, et al. Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery: a report from the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1992;86:446-457.PubMedGoogle Scholar
  29. 28.
    Jones EL, Craver JM, Guyton RA, et al. Importance of complete revascularization in performance of the coronary bypass operation. Am J Cardiol. 1983;51:7-12.PubMedCrossRefGoogle Scholar
  30. 29.
    Samady H, Elefteriades JA, Abbott BG, et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100:1298-1304.PubMedGoogle Scholar
  31. 30.
    Pagano D, Lewis ME, Townend JN, et al. Coronary revascularization for postischemic heart failure: how myocardial viability affects survival. Heart. 1990;82:684-688.Google Scholar
  32. 31.
    Podio V, Spinnler MT, Bertuccio G, et al. Prognosis of hibernating myocardium is independent of recovery of function: evidence from a routine based follow up study. Nucl Med Commun. 2002;23:933-942.PubMedCrossRefGoogle Scholar
  33. 32.
    Chaudhry FA, Tauke JT, Alessandrini RS, et al. Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 1999;34:730-738.PubMedCrossRefGoogle Scholar
  34. 33.
    Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation-preliminary study in pigs. Radiology. 2000;214:801-807.PubMedGoogle Scholar
  35. 34.
    Poon M, Fuster V, Fayad Z. Cardiac magnetic resonance imaging: a “one-stop-shop” evaluation of myocardial dysfunction. Curr Opin Cardiol. 2002;17:663-670.PubMedCrossRefGoogle Scholar
  36. 35.
    Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215-223.PubMedGoogle Scholar
  37. 36.
    Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.PubMedGoogle Scholar
  38. 37.
    Gupta A, Lee VS, Chung YC, Babb JS, Simonetti OP. Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology. 2004;233:921-926.PubMedCrossRefGoogle Scholar
  39. 38.
    Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation. 1998;98:268-294.Google Scholar
  40. 39.
    Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced MRI to identify reversible myocardial dysfunction. N Engl J Med. 2006;343:1445-1453.CrossRefGoogle Scholar
  41. 40.
    Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21-28.PubMedCrossRefGoogle Scholar
  42. 41.
    Schinkel AF, Bax JJ, Poldermans D. Clinical assessment of myocardial hibernation. Heart. 2005;91:111-117.PubMedCrossRefGoogle Scholar
  43. 42.
    Judd RM, Wagner A, Rehwald WG, Albert T, Kim RJ. Technology insight: assessment of myocardial viability by delayed-enhancement magnetic resonance imaging. Nat Clin Pract Cardiovasc Med. 2005;2(3):150-158.PubMedCrossRefGoogle Scholar
  44. 43.
    Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients with signs and symptoms of coronary artery disease. Circulation. 2006;113:2733-2743.PubMedCrossRefGoogle Scholar
  45. 44.
    Yan AT, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32-39.PubMedCrossRefGoogle Scholar
  46. 45.
    Reddy VY, Malchano ZJ, Holmvang G, et al. Integration of cardiac magnetic resonance imaging with three-dimensional electroanatomic mapping to guide left ventricular catheter manipulation: feasibility in a porcine model of healed myocardial infarction. J Am Coll Cardiol. 2004;44(11):2202-2213.PubMedCrossRefGoogle Scholar
  47. 46.
    Bogun F, Desjrdins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53:1138-1145.PubMedCrossRefGoogle Scholar
  48. 47.
    Fahmy TS, Wazni OM, Jaber WA, et al. Integration of positron emission tomography/computed tomography with electroanatomical mapping: a novel approach for ablation of scar-related ventricular tachycardia. Heart Rhythm. 2008;5(11):1538-1545.PubMedCrossRefGoogle Scholar
  49. 48.
    Tian J, Smith MF, Chinnadurai P, et al. Clinical application of PET/CT fusion imaging for three-dimensional myocardial scar and left ventricular anatomy during ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2009;20:597-604.CrossRefGoogle Scholar
  50. 49.
    Thompson PL, Fletcher EE, Katavatis V. Enzymatic indices of myocardial necrosis: influence on short- and long-term prognosis after myocardial infarction. Circulation. 1979;59:113-119.PubMedGoogle Scholar
  51. 50.
    Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94(6):730-736.PubMedCrossRefGoogle Scholar
  52. 51.
    van der Burg AE, Bax JJ, Boersma E, Pauwels EK, van der Wall EE, Schalij MJ. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation. 2003;108(16):1954-1959.PubMedCrossRefGoogle Scholar
  53. 52.
    Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54(3):242-249.PubMedCrossRefGoogle Scholar
  54. 53.
    Roes SD, Kelle S, Kaandorp TA, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol. 2007;100:930-936.PubMedCrossRefGoogle Scholar
  55. 54.
    Bello D, Fieno DS, Kim RJ, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol. 2005;45:1104-1108.PubMedCrossRefGoogle Scholar
  56. 55.
    Kadish A, Bello D, Finn JP, et al. Rationale and Design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. J Cardiovasc Electrophysiol. 2009;20(9):982-987.PubMedCrossRefGoogle Scholar
  57. 56.
    de Leeuw N, Ruiter DJ, Balk AH. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int. 2001;14:299-306.PubMedCrossRefGoogle Scholar
  58. 57.
    McCrohon J, Moon J, Prasad S, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-59.PubMedCrossRefGoogle Scholar
  59. 58.
    Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.PubMedCrossRefGoogle Scholar
  60. 59.
    Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821-2825.PubMedCrossRefGoogle Scholar
  61. 60.
    Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonanceheralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414-2421.PubMedCrossRefGoogle Scholar
  62. 61.
    Cheong BY, Muthupillai R, Wilson JM, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120(21):2069-2076.PubMedCrossRefGoogle Scholar
  63. 62.
    Fernandes VR, Wu KC, Rosen BD, et al. Enhanced infarct border zone function and altered mechanical activation predict inducibility of monomorphic ventricular tachycardia in patients with ischemic cardiomyopathy. Radiology. 2007;245(3):712-719.PubMedCrossRefGoogle Scholar
  64. 63.
    Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115(15):2006-2014.PubMedCrossRefGoogle Scholar
  65. 64.
    Roes SD, Borleffs CJ, van der Geest RJ, et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2(3):183-190.PubMedCrossRefGoogle Scholar
  66. 65.
    Klocke FJ, Wu E, Lee DC. “Shades of gray” in cardiac magnetic resonance images of infarcted myocardium. Can they tell us what we’d like them to? Circulation. 2006;114:8-10.PubMedCrossRefGoogle Scholar
  67. 66.
    Wagner A, Mahrholdt H, Thomson L, et al. Effects of time, dose and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging – delayed contrast enhancement. J Am Coll Cardiol. 2006;47:2027-2033.PubMedCrossRefGoogle Scholar
  68. 67.
    Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172.PubMedGoogle Scholar
  69. 68.
    Frances RJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. Int J Cardiol. 2006;110:279-287.PubMedCrossRefGoogle Scholar
  70. 69.
    Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005;112(5):636-642.PubMedCrossRefGoogle Scholar
  71. 70.
    Hamilton R. Arrhythmogenic right ventricular cardiomyopathy. PACE. 2009;32:S44-S51.PubMedGoogle Scholar
  72. 71.
    McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994;71(3):215-218.PubMedCrossRefGoogle Scholar
  73. 72.
    Jain A, Tandri H, Calkins H, Bluemke DA. Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Magn Reson. 2008;10(32):1-14.Google Scholar
  74. 73.
    Tandri H, Bomma C, Calkins H, Bluemke DA. Magnetic resonance and computed tomography imaging of arrhythmogenic right ventricular dysplasia. J Magn Reson Imaging. 2004;19(6):848-858.PubMedCrossRefGoogle Scholar
  75. 74.
    Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45(1):98-103.PubMedCrossRefGoogle Scholar
  76. 75.
    Wijnmaalen AP, Schalij MJ, Bootsma M, et al. Patients with scar-related right ventricular tachycardia: determinants of long-term outcome. J Cardiovasc Electrophysiol. 2009;20(10):1119-1127.PubMedCrossRefGoogle Scholar
  77. 76.
    Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation. 1998;97(16):1571-1580.PubMedGoogle Scholar
  78. 77.
    Fontaliran F, Fontaine G, Fillette F, Aouate P, Chomette G, Grosgogeat Y. Nosologic frontiers of arrhythmogenic dysplasia: quantitative variations of normal adipose tissue of the right heart ventricle. Arch Mal Coeur Vaiss. 1991;84:33-38.PubMedGoogle Scholar
  79. 78.
    Shirani J, Berezowski K, Roberts WC. Quantitative measurement of normal and excessive (coradiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage. Am J Cardiol. 1995;76:414-418.PubMedCrossRefGoogle Scholar
  80. 79.
    Macedo R, Prakasa K, Tichnell C, et al. Marked lipomatous infiltration of the right ventricle: MRI findings in relation to arrhythmogenic right ventricular dysplasia. AJR Am J Roentgenol. 2007;188(5):W423-W427.PubMedCrossRefGoogle Scholar
  81. 80.
    Pfluger HB, Phrommintikul A, Mariani JA, Cherayath JG, Taylor AJ. Utility of myocardial fibrosis and fatty infiltration detected by cardiac magnetic resonance imaging in the diagnosis of arrhythmogenic right ventricular dysplasia – a single centre experience. Heart Lung Circ. 2008;17(6):478-483.PubMedCrossRefGoogle Scholar
  82. 81.
    Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373.PubMedCrossRefGoogle Scholar
  83. 82.
    Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.PubMedCrossRefGoogle Scholar
  84. 83.
    Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.PubMedCrossRefGoogle Scholar
  85. 84.
    Maron B, Spirito P, Shen WK, Haas TS, Formisano F, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-412.PubMedCrossRefGoogle Scholar
  86. 85.
    Frenneaux MP, Counihan PJ, Caforio AL, et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82:1995-2002.PubMedCrossRefGoogle Scholar
  87. 86.
    Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987-2991.PubMedGoogle Scholar
  88. 87.
    Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-2264.PubMedCrossRefGoogle Scholar
  89. 88.
    Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22(6):901.CrossRefGoogle Scholar
  90. 89.
    Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-1374.PubMedCrossRefGoogle Scholar
  91. 90.
    Dimitrow PPKP, Vliengenthart R, Pasowicz M, et al. Late hyperenhancement in gadolinium magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging. 2008;24(1):85-87.Google Scholar
  92. 91.
    Paya E, Marin F, Gonzalez J, Gimeno JR, Feliu E, et al. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail. 2008;14:414-419.PubMedCrossRefGoogle Scholar
  93. 92.
    Dumont C, Monserrat L, Soler R, et al. Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophiccardiomyopathy. Rev Esp Cardiol. 2007;60(1):15-23.PubMedCrossRefGoogle Scholar
  94. 93.
    Suk T, Edwards C, Hart H, Christiansen JP. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ. 2008;17(5):370-374.PubMedCrossRefGoogle Scholar
  95. 94.
    Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(1):51-58.PubMedCrossRefGoogle Scholar
  96. 95.
    Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001;104(12):1380-1384.PubMedCrossRefGoogle Scholar
  97. 96.
    Maron BJ, Kragel AH, Roberts WC. Sudden death in hypertrophic cardiomyopathy with normal left ventricular mass. Br Heart J. 1990;63:308-310.PubMedCrossRefGoogle Scholar
  98. 97.
    Maron BJ, Wolfson JK, Roberts WC. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:785-790.PubMedCrossRefGoogle Scholar
  99. 98.
    Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2(1):34-44.PubMedCrossRefGoogle Scholar
  100. 99.
    Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21.PubMedCrossRefGoogle Scholar
  101. 100.
    Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5 year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.PubMedGoogle Scholar
  102. 101.
    Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26-31.PubMedGoogle Scholar
  103. 102.
    Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211.PubMedGoogle Scholar
  104. 103.
    Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients and review of 78 previously described necropsy patients. Am J Med. 1977;63:86-108.PubMedCrossRefGoogle Scholar
  105. 104.
    Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians London. 1981;15:245-246. 249–523.Google Scholar
  106. 105.
    Fleming HA, Bailey SA. The prognosis of sarcoid heart disease in the United Kingdom. Ann N Y Acad Sci. 1986;465:543-550.PubMedCrossRefGoogle Scholar
  107. 106.
    Vignaux O, Dhôte R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis. A 1 year follow-up study. Chest. 2002;122:1895-1901.PubMedCrossRefGoogle Scholar
  108. 107.
    Cheong BYC, Muthupillai R, Nemeth M, et al. The utility of delayed-enhancement magnetic resonance imaging for identifying nonischemic myocardial fibrosis in asymptomatic patients with biopsy-proven systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:39-46.PubMedGoogle Scholar
  109. 108.
    Smedema JP, Snoep G, Van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690.PubMedCrossRefGoogle Scholar
  110. 109.
    Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969-1977.PubMedCrossRefGoogle Scholar
  111. 110.
    Hiraga H, Yuwa K, Hiroe M. Guideline for the Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Disease [in Japanese]. Tokyo: The Japanese Ministry of Health and Welfare.1993:23-24.Google Scholar
  112. 111.
    Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.PubMedCrossRefGoogle Scholar
  113. 112.
    Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;248:1639-1646.CrossRefGoogle Scholar
  114. 113.
    Murphy RT, Thaman R, Blanes JG, et al. Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J. 2005;26:1144-1145.CrossRefGoogle Scholar
  115. 114.
    Habib G, Charron P, Eicher JC, et al. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients. Results from a French registry. Eur J Hear Fail. 2010;13(2):177-185. Epub 2010 Dec 29.CrossRefGoogle Scholar
  116. 115.
    Yousef ZR, Foley PW, Khadjooi K, et al. Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging. BMC Cardiovasc Disord. 2009;9:37.PubMedCrossRefGoogle Scholar
  117. 116.
    Sosnovik DE, Wang R, Dai G, et al. Diffusion spectrum MRI tractography reveals the presence of a complex network of residual myofibers in infarcted myocardium. Circ Cardiovasc Imaging. 2009;2:206-212.PubMedCrossRefGoogle Scholar
  118. 117.
    Sosnovik DE, Wang R, Dai G, Reese TG, Wedeen VJ. Diffusion MR tractography of the heart. J Cardiovasc Magn Reson. 2009;11:47.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Experimental Electrophysiology Laboratory, Department of MedicineMassachusetts General HospitalBostonUSA
  2. 2.Massachusetts General Hospital Heart CenterBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations